Verona Pharma's ensifentrine is a first-in-class, inhaled, dual inhibitor of the enzymes PDE3 and PDE4, targeting both bronchodilation and inflammation. Positive Phase 3 results from the ENHANCE ...
LONDON and RALEIGH, N.C., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces ...
The recent Food and Drug Administration (FDA) approval of ensifentrine marks the first new treatment for patients with persistent chronic obstructive pulmonary disease (COPD) in more than a decade, ...
Please provide your email address to receive an email when new articles are posted on . Patient experts expressed excitement over ensifentrine’s ability to lower exacerbations. If priced between ...
LONDON and RALEIGH, N.C., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces it ...
Please provide your email address to receive an email when new articles are posted on . Ensifentrine had favorable efficacy and safety profiles in two phase 3 trials. Verona Pharma is prepared for ...
Verona Pharma plc develops respiratory disease medicines, with its lead asset being ensifentrine, an inhaled dual inhibitor of PDE3 and PDE4 enzymes. Ensifentrine is being developed in multiple ...
LONDON and RALEIGH, N.C., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, ...
Verona Pharma has sold the rights to chronic obstructive pulmonary disease (COPD) drug candidate ensifentrine in greater China to Nuance Pharma for $40 million upfront. A nebulized formulation of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results